Huma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients - Seite 2

informative summaries of the treatment options available for patients and
relatives to absorb, so that they can approach treatment with a more positive
mindset, and by being well informed about the effects that treatment may have on
them, it would help facilitate them to continue with their day-to-day living."

A Commitment to Advancing Patient Care

Dan Vahdat, Founder and CEO of Huma, said: "We are excited to launch this
innovative app in partnership with Merck KGaA, Darmstadt, Germany, furthering
our mission to transform healthcare with a digital-first approach. By empowering
patients with access to personalised resources and support, we believe we can
make a meaningful difference in the lives of those affected by bladder cancer."

Dr. Mert Aral, Chief Medical Officer at Huma, said: "This initiative is designed
to demystify the often overwhelming journey faced by cancer patients. Our
objective is clear - to improve patients' understanding of their condition,
enable smooth navigation through complex care pathways, and promote consistent
adherence to their treatments. The UK debut marks the inception of our
partnership's endeavour to offer comprehensive guidance and unwavering support
to all individuals battling cancer."

About Huma

Huma Therapeutics is a global digital health technology company that advances
digital-first care delivery and research to help people live longer, fuller
lives. Its award-winning technology platform is used by more than 3,000
hospitals and clinics, with over 1.8 million active users in healthcare and over
700,000 participants across research.

Huma's technology powers:

- virtual care tools ranging from digital-first screening and population health
initiatives to at-scale remote patient monitoring (RPM)
- companion apps to support patients through treatment and drug therapies
- digital clinical trials, including decentralised trials, to accelerate medical
research

Huma's regulated Software as a Medical Device (SaMD) platform is the first
disease- and device-agnostic platform to achieve EU MDR Class IIb, US FDA 510(k)
Class II and Saudi Class C regulatory clearance. The SaMD platform is regulated
to accept artificial intelligence algorithms and monitor patients of all ages.

View original content: https://www.prnewswire.co.uk/news-releases/huma-and-merck
-kgaa-darmstadt-germany-launch-innovative-app-to-support-bladder-cancer-patients
-302129830.html

Contact:

Meena Tafazzoli,
[phone],
[e-mail]

Additional content: http://presseportal.de/pm/167548/5767904
OTS: HUMA Therapeutics